Risk of Metabolic Complications in Patients with Solid Tumors Treated with mTOR inhibitors: Meta-analysis Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Monday, April 11, 2016

Risk of Metabolic Complications in Patients with Solid Tumors Treated with mTOR inhibitors: Meta-analysis



open access:
Risk of Metabolic Complications in Patients with Solid Tumors Treated with mTOR inhibitors: Meta-analysis

 Despite its limitations, this study demonstrates that the use of mTORi is associated with a significant risk of developing all- and high-grade metabolic complications. The risk of adverse metabolic events does not differ by type of Rapamycin analog, type of malignancy treated, or when monotherapy or concomitant therapy is utilized. Early detection and effective management of HGL, HTG, and HCE may allow for more extensive use of mTORi therapy, especially in cancer patients with pre-existing metabolic comorbidities, and should limit treatment related toxicity.

0 comments :

Post a Comment

Your comments?